Compare Abbott Laboratories (ABT) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Fiverr International Ltd — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Fiverr International Ltd trades at $10.86 (market cap $403.37M). The key difference: Abbott Laboratories is far larger — about 413.9× Fiverr International Ltd's market cap, and Abbott Laboratories pays a 2.63% dividend while Fiverr International Ltd pays none. Which is the better fit depends on your goals.
| ABT | FVRR | |
|---|---|---|
Market Cap | $166.94B | $403.37M |
Sector | Health | Industrials |
52-Week High | $136.62 | $27.77 |
52-Week Low | $82.57 | $9.62 |
Enterprise Value | $193.69B | $133.97M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
Fiverr International (FVRR) trades at $11.22, up 3.79% today, showing signs of recovery from recent lows. The stock appears fundamentally undervalued with a P/E of 14.44 and P/S of 0.96, while revenue growth has been steady from $337M in 2022 to $431M in 2025. Recent earnings show mixed results with Q1 2026 missing expectations, but technical indicators suggest bullish momentum with strong moving average support.
FVRR presents a contrarian opportunity with attractive valuation metrics and improving profitability, though investor sentiment remains cautious due to active buyer declines and ongoing legal investigations. The company's strategy shift and strong gross margins of 81.86% provide upside potential, but competitive pressures and execution risks require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
